EP Patent

EP3691647A1 — New treatment of sma

Assigned to F Hoffmann La Roche AG · Expires 2020-08-12 · 6y expired

What this patent protects

The present invention relates to 7- (4,7-diazaspiro [2.5] octan-7-yl) -2- (2,8-dimethylimidazo [1,2-b] pyridazin-6-yl) pyrido [1,2- a] pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition for use in the treatment of SMA, its me…

USPTO Abstract

The present invention relates to 7- (4,7-diazaspiro [2.5] octan-7-yl) -2- (2,8-dimethylimidazo [1,2-b] pyridazin-6-yl) pyrido [1,2- a] pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition for use in the treatment of SMA, its methods of treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP3691647A1
Jurisdiction
EP
Classification
—
Expires
2020-08-12
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.